Eli Lilly seeks emergency use authorization for effective antibody treatment
Eli Lilly has determined its monoclonal antibody treatment reduces patients' COVID-19 viral load and helps them avoid hospitalization, it announced Wednesday.
The treatment involves combining two antibodies and injecting them into patients — similar to the treatment developed by Regeneron that President Trump received. Less than 1 percent of patients sick with COVID-19 and injected with the treatment went to the hospital, compared to 5.8 percent who had a placebo, Eli Lilly's study found. And at the end of 11 days, the antibody combination "significantly reduced" the amount of virus found in patients' nasal swabs.
Last month, the pharmaceutical company also announced positive results from a trial involving just one antibody. Eli Lilly is now seeking the Food and Drug Administration's emergency use authorization for the single antibody treatment. It will likely seek authorization for the combination therapy next month, after it manufactures a bigger supply and gets patients into clinical trials.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Wednesday's news sent Eli Lilly's shares up more than 3 percent in morning trading.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Kathryn is a graduate of Syracuse University, with degrees in magazine journalism and information technology, along with hours to earn another degree after working at SU's independent paper The Daily Orange. She's currently recovering from a horse addiction while living in New York City, and likes to share her extremely dry sense of humor on Twitter.
-
North Carolina Supreme Court risks undermining its legitimacy
Under the radar A contentious legal battle over whether to seat one of its own members threatens not only the future of the court's ideological balance, but its role in the public sphere
By Rafi Schwartz, The Week US Published
-
Codeword: January 14, 2025
The Week's daily codeword puzzle
By The Week Staff Published
-
Sudoku hard: January 14, 2025
The Week's daily hard sudoku puzzle
By The Week Staff Published
-
US port strike averted with tentative labor deal
Speed Read The strike could have shut down major ports from Texas to Maine
By Peter Weber, The Week US Published
-
Biden expected to block Japanese bid for US Steel
Speed Read The president is blocking the $14 billion acquisition of U.S. Steel by Japan's Nippon Steel, citing national security concerns
By Peter Weber, The Week US Published
-
Judges block $25B Kroger-Albertsons merger
Speed Read The proposed merger between the supermarket giants was stalled when judges overseeing two separate cases blocked the deal
By Peter Weber, The Week US Published
-
Rupert Murdoch loses 'Succession' court battle
Speed Read Murdoch wanted to give full control of his empire to son Lachlan, ensuring Fox News' right-wing editorial slant
By Peter Weber, The Week US Published
-
Bitcoin surges above $100k in post-election rally
Speed Read Investors are betting that the incoming Trump administration will embrace crypto
By Peter Weber, The Week US Published
-
Enron mystery: 'sick joke' or serious revival?
Speed Read 23 years after its bankruptcy filing, the Texas energy firm has announced its resurrection
By Peter Weber, The Week US Published
-
US charges Indian tycoon with bribery, fraud
Speed Read Indian billionaire Gautam Adani has been indicted by US prosecutors for his role in a $265 million scheme to secure solar energy deals
By Peter Weber, The Week US Published
-
Boeing machinists approve contract, end strike
Speed Read The company's largest union approved the new contract offer, ending a seven-week strike
By Peter Weber, The Week US Published